Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Study of Velcade and Temsirolimus for Relapsed or Refractory Non-Hodgkin Lymphoma

11 décembre 2019 mis à jour par: University of Wisconsin, Madison

A Phase II Study of Velcade and Temsirolimus for Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

The investigators want to find out if the drugs Velcade and temsirolimus given together are effective in treating cancer. Velcade and temsirolimus are each FDA approved individually for certain types of cancer (Velcade for multiple myeloma and mantle cell lymphoma, and temsirolimus for renal cell carcinoma) but are not currently approved in combination for B-cell non-Hodgkin lymphoma. The investigators are trying to find out if giving these 2 drugs together will improve the period of time that the patient's cancer is stopped or slowed from growing and causing symptoms.

Aperçu de l'étude

Statut

Complété

Les conditions

Intervention / Traitement

Type d'étude

Interventionnel

Inscription (Réel)

40

Phase

  • Phase 2

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

  • États-Unis
    • South Dakota
      • Rapid City, South Dakota, États-Unis, 57701
        • Rapid City Regional Hospital John T. Vucurevich Cancer Care Institute
    • Wisconsin
      • Green Bay, Wisconsin, États-Unis, 54143
        • Aurora Baycare Medical Center-GreenBay
      • Green Bay, Wisconsin, États-Unis, 54301
        • St Vincent Regional Cancer Center CCOP
      • Green Bay, Wisconsin, États-Unis, 54313
        • Bellin Memorial Hospital, Inc
      • La Crosse, Wisconsin, États-Unis, 54601
        • Gunderson Lutheran Health System
      • Madison, Wisconsin, États-Unis, 53715
        • UW Health Oncology- 1 S Park
      • Madison, Wisconsin, États-Unis, 53792
        • University of Wisconsin Cancer Center
      • Marinette, Wisconsin, États-Unis
        • Aurora BayCare Medical Center
      • Marshfield, Wisconsin, États-Unis, 54449
        • Marshfield Clinic
      • Milwaukee, Wisconsin, États-Unis, 53226
        • Medical College of Wisconsin
      • Milwaukee, Wisconsin, États-Unis, 53211
        • Columbia St Mary's, Inc
      • Sheboygan, Wisconsin, États-Unis, 53081
        • Aurora Sheboygan Memorial Medical Center
      • Summit, Wisconsin, États-Unis, 53066
        • Aurora Medical Center in Summit
      • Two Rivers, Wisconsin, États-Unis, 54241
        • Aurora Medical Center in Two Rivers
      • Waukesha, Wisconsin, États-Unis, 53188
        • Waukesha Memorial Hospital
      • Wausau, Wisconsin, États-Unis, 54401
        • Aspirus Wausau Hospital
      • Wauwatosa, Wisconsin, États-Unis, 53226
        • Aurora Health Care Metro, Inc.
      • Wisconsin Rapids, Wisconsin, États-Unis, 54494
        • UW Cancer Center-Riverview

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • Relapsed or refractory B-cell non-Hodgkin lymphoma which includes: diffuse large B-cell lymphoma; primary mediastinal large B-cell lymphoma; follicular lymphoma (grade 1, 2 or 3); mantle cell lymphoma; small lymphocytic lymphoma; marginal zone lymphoma; lymphoplasmacytic lymphoma; B-cell lymphoblastic lymphoma; or Burkitt lymphoma. "Grey-zone" lymphomas must be approved by the Wisconsin Oncology Network (WON) Study Chair or Principal Investigator prior to enrollment.
  • At least one measurable tumor mass (>1.5 cm in the long axis and > 1.0 cm in the short axis) that has not been previously irradiated, or has grown since previous irradiation.
  • Documented relapse or progression following prior antineoplastic therapy.
  • No clinical or documented radiographic evidence of central nervous system lymphoma.
  • Eastern Cooperative Oncology Group [ECOG] performance status of 0-2.
  • The following clinical laboratory values within 14 days prior to enrollment:
  • Absolute neutrophil count (ANC) ≥ 1.5 x 109 cells / L
  • Platelets ≥ 100 x 109 cells / L
  • Alanine transaminase (ALT) and Aspartate transaminase (AST) ≤ 3X the upper limit of normal (ULN)
  • Total bilirubin ≤ 2X the upper limit of normal (ULN).
  • Calculated creatinine clearance ≥40 mL/min (using the Cockcroft-Gault equation).
  • Female subjects must be either post-menopausal for at least 1 year or surgically sterilized, agree to practice 2 effective methods of contraception from the time of signing the informed consent form through 30 days after the last dose of Velcade, or agree to completely abstain from heterosexual intercourse.
  • Male subjects, even if surgically sterilized (ie, status postvasectomy) must agree to 1 of the following: practice effective barrier contraception during the entire study treatment period and through a minimum of 30 days after the last dose of study drug, or completely abstain from heterosexual intercourse.

Exclusions:

  • Antineoplastic, experimental, or radiation therapy within 14 days prior to enrollment, or 21 days prior to Day 1 of Cycle 1.
  • Radioimmunoconjugates within 10 weeks of Day 1 of Cycle 1.
  • Autologous stem cell transplant within 3 months before Day 1 of Cycle 1, or any prior history of allogeneic stem cell transplant.
  • Platelet transfusion within 7 days of Day 1 of Cycle 1.
  • Ongoing therapy with glucocorticoids. Prednisone ≤15 mg per day or its equivalent is allowed.
  • Patient has Grade 2 or greater peripheral neuropathy within 14 days before enrollment.
  • Myocardial infarction within 6 months prior to enrollment or has New York Heart Association (NYHA) Class III or IV heart failure (see section 8.4), uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities.
  • Patient has hypersensitivity to Velcade, boron or mannitol.
  • Female subjects that are pregnant or breast-feeding.
  • Serious medical or psychiatric illness that is likely to interfere with participation
  • Diagnosed or treated for another malignancy within 2 years of enrollment, with the exception of complete resection of basal cell carcinoma or squamous cell carcinoma of the skin, an in situ malignancy, or low-risk prostate cancer after curative therapy.
  • Prior therapy with both Velcade and temsirolimus. Patients who have previously been treated with either Velcade or temsirolimus (but not both) are eligible.
  • Radiation therapy within 3 weeks before randomization.
  • Patients must not be taking the following strong CyP3A inducers at study entry: phenytoin, phenobarbital, rifampin, carbamazepin, rifabutin, rifampicin, a one week washout period is required.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: N / A
  • Modèle interventionnel: Affectation à un seul groupe
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Velcade plus Temsirolimus

Velcade 1.6 mg/m2 weekly (days 1, 8, 15, and 22) Temsirolimus 25mg IV weekly (days 1, 8, 15, 22, and 29)

Treat for up to 6 cycles, cycles are 35 days long.
Médicament: Velcade
Velcade, 1.6 mg/m2 weekly (days 1, 8, 15, and 22)
Autres noms:
  • bortezomib, PS-341
Médicament: Temsirolimus
Temsirolimus 25mg IV weekly (days 1, 8, 15, 22, and 29)
Autres noms:
  • Torisel

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Overall Response Rate
Délai: Up to 60 months
The primary objective of this study is to determine whether Velcade in combination with temsirolimus provides benefit to subjects with relapsed or refractory B-cell non-Hodgkin lymphoma as assessed by overall response rate (ORR) to therapy. ORR is the sum of patients with a Complete Response and Partial Response to therapy. Per Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete REsponse (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.
Up to 60 months
Progression Free Survival
Délai: Up to 60 months
The primary objective of this study is to determine whether Velcade in combination with temsirolimus provides benefit to subjects with relapsed or refractory B-cell non-Hodgkin lymphoma as assessed by progression-free survival (PFS).
Up to 60 months

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Safety of This Regimen
Délai: Up to 36 months
Safety of the regimen will be measured by frequency and severity of adverse events.
Up to 36 months
Complete Response Rate
Délai: Up to 60 months
The complete response rate (CR) to therapy as defined by International Lymphoma Response Criteria.
Up to 60 months
Tolerability of the Regimen
Délai: Up to 36 months
Tolerability of the regimen is measured by the number of subjects able to complete the therapy as planned.
Up to 36 months
Duration of Response
Délai: Up to 60 months
Duration of Response is how long a response to therapy is held before a subject has progressive disease.
Up to 60 months
Overall Survival
Délai: Up to 60 months
Length of time from enrollment until death.
Up to 60 months

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

University of Wisconsin, Madison

Collaborateurs

National Cancer Institute (NCI)
Pfizer
Millennium Pharmaceuticals, Inc.

Les enquêteurs

  • Chercheur principal: Brad S Kahl, MD, Universtity of Wisconsin- Madison
  • Chaise d'étude: Timothy S Fenske, MD, Medical College of Wisconsin

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude

1 février 2011

Achèvement primaire (Réel)

1 octobre 2013

Achèvement de l'étude (Réel)

1 juin 2014

Dates d'inscription aux études

Première soumission

20 janvier 2011

Première soumission répondant aux critères de contrôle qualité

21 janvier 2011

Première publication (Estimation)

24 janvier 2011

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

13 décembre 2019

Dernière mise à jour soumise répondant aux critères de contrôle qualité

11 décembre 2019

Dernière vérification

1 juillet 2017

Plus d'information

Termes liés à cette étude

Mots clés

Termes MeSH pertinents supplémentaires

Autres numéros d'identification d'étude

  • HO10407
  • A534260 (Autre identifiant: UW Madison)
  • SMPH\MEDICINE\HEM-ONC (Autre identifiant: UW Madison)
  • H-2010-0393 (Autre identifiant: IRB)
  • NCI-2011-00647 (Identificateur de registre: NCI Trial ID)

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner